Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real World Study Evaluating the Persistence and Adherence of Subcutaneously Administered Biologics in Patients with Psoriatic Arthritis seen in Routine Clinical Practice

Next Previous
X
Search
Trial Profile

A Real World Study Evaluating the Persistence and Adherence of Subcutaneously Administered Biologics in Patients with Psoriatic Arthritis seen in Routine Clinical Practice

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Secukinumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation

    • Most Recent Events

    • 16 Jun 2018 Results (n=1558) assessing the persistence of subcutaneously (SC) administered biologics in patients with psoriatic arthritis over 12 months of follow-up, presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 23 May 2018 Results (n=1558) presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 12 Dec 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top